To further validate the upregulation of TINCR, we included 30 tissue samples from HER-2+ breast cancer patients exhibiting poor response to trastuzumab therapy and another 30 tissue samples from HER-2+ breast cancer patients responding to trastuzumab therapy. Here, ERBB2 is linked to breast carcinoma.